Member Info for Krone

RMM - absolutely, grant funding will be diddly squat and JR implied that the hoops they would have to jump through to get it would be onerous. This seems like something much much bigger.

Hi RMM - spoken as one true believer to another!

Stoney - thanks for the excellent posts. All bodes well for Sareum!!

https://newsfilter.io/a/aeab504fece91279a18e757ce862b345

https://twitter.com/sareumplc/status/1250737407340748800?s=21

Stoney, very nice, thank you.

Hi Thoth, I agree, particularly given the contradiction of the apparently blasé reference to grant funding by John Reader against what for Sareum is a veritable deluge of tweets on the C19 issue! Something must be up and it could be very big indeed!

Hi Fadec, do you have access to the paper referred to at https://twitter.com/elschemistry/status/1250370806259109888?s=21

https://twitter.com/sareumplc/status/1250384484203102210?s=21

https://twitter.com/sareumplc/status/1250381903200387073?s=21

Basser1 - done

Thanks Stoney

Oops - Japanese

https://twitter.com/jmedj_news/status/1250278557294575616?s=21

https://twitter.com/hybridanllp/status/1249957135187836935?s=21

Hi Amber, just context, given the current C19 speculation, as is the previously posted https://www.cambridgenetwork.co.uk/news/link-china-pharma-solutions-brokers-sareum-co-development-a6880

Just for interest: https://twitter.com/sareumplc/status/460711110065131520?s=21

Hi RMM - thanks, that sounds realistic. Just hope that the potentially massive opportunities created by the current unique set of circumstances aren’t missed. Stephen Parker will hopefully show his mettle and get Sareum in the fast lane!

RMM - so +/- £12b lovely!
What timescale do your calculations envisage given the potentially significant relaxation of trial requirements in the current circumstances in respect of C19. It will be interesting to see if super fast approvals are granted for non C19 targets.

Results in 2 months!
The study will investigate the efficacy and safety of baricitinib as a potential treatment for hospitalized patients diagnosed with COVID-19, beginning this month in the U.S. with a planned expansion to additional sites including Europe and Asia. Results are expected within the next two months.